<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We present the case of a 71 year-old man with secondary <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo>, who was successfully treated with low dose melphalan plus Epo plus G-CSF </plain></SENT>
<SENT sid="1" pm="."><plain>We treated the patient with 2 mg of melphalan once a day orally, G-CSF 5 mg/kg 3 times a week and Epo 10.000 ui subcutaneously 3 times a week until the maximum response was obtained </plain></SENT>
<SENT sid="2" pm="."><plain>Complete remission was achieved after 16 weeks of continuous treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment-related toxicity was not significant </plain></SENT>
<SENT sid="4" pm="."><plain>We recommend the use of low dose melphalan in elderly patients with high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> as a treatment option </plain></SENT>
</text></document>